-
Endoscopic procedure DBE transforms small intestine diagnosis and treatment
04 May 2024 02:40 GMT
In a medical breakthrough that promises hope for individuals battling small intestine disorders, a pioneering endoscopic procedure known as Double Balloon Enteroscopy (DBE) is making waves, according to Dheeraj Chaudhri, head of Endoscopy Division & …
-
Low-Dose Naltrexone in Gastroenterology: A Bonafide ‘Wonder Drug’
03 May 2024 18:31 GMT
St. Louis, MO, May 03, 2024 (GLOBE NEWSWIRE) -- Dr. Leonard Weinstock, a leading gastroenterologist, delves into the promising realm of low-dose naltrexone (LDN) in his recent byline article. Dr. Weinstock's insightful piece sheds light on the …
-
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease
01 May 2024 17:12 GMT
Submission included data from the Phase 3 QUASAR program in ulcerative colitis and the Phase 3 GALAXI program in Crohn's disease, which each achieved their primary endpoints1,2
BEERSE, Belgium, May 1, 2024 /PRNewswire/ -- Janssen-Cilag …
-
Weight-Loss Drugs Fuel Rise in US Prescription Spending
02 May 2024 19:00 GMT
In 2023, prescription drug spending grew 13.6% compared with 2022 and semaglutide was the highest selling drug due to a recent increase of weight-loss classifications.
“Expenditures for semaglutide doubled last year, making it the new top-selling drug in …
-
FDA Approves High-Concentration, Citrate-Free Cyltezo for the Treatment of Chronic Inflammatory Diseases
02 May 2024 12:35 GMT
The FDA has approved adalimumab-adbm (Cyltezo; Boehringer Ingelheim), a high-concentrated, citrate-free formulation biosimilar to Humira (adalimumab; AbbVie) for the treatment of multiple chronic inflammatory diseases. The approval is partly based on data …
-
Garvan Institute and Illumina collaborate to transform the treatment of complex diseases
01 May 2024 02:30 GMT
Illumina, a global genomics and human health company, has partnered with the Garvan Institute of Medical Research's TenK10K project to help transform the treatment of complex diseases, starting with autoimmune diseases, with a joint investment of $27 …
-
Will the DEA reclassify weed as a Schedule III drug? What we know
01 May 2024 02:26 GMT
As Kentucky heads toward the legalization of medicinal marijuana at the beginning of 2025 and the possible legalization of recreational marijuana at a later date, the U.S. Drug and Enforcement Administration is debating reclassifying weed as a less …
-
I'm the Gut Health Doctor, here are my top tips to ease IBS symptoms
04 May 2024 07:51 GMT
It's an agonising condition that blights the lives of millions.
But there's help on hand for irritable bowel syndrome (IBS) sufferers.
A prominent expert nicknamed the Gut Health Doctor has revealed her best tips to ease any digestive discomfort.
…
-
IBD Drug Development Tools: TL1A Recombinant Proteins and Overexpression Cell Lines
29 Apr 2024 01:40 GMT
IBD is one of important autoimmune disease, including ulcerative colitis and Crohn's disease. Drug treatment targeting TL1A can effectively alleviate the clinical symptoms of IBD. In order to meet the development of drugs targeting the TL1A / DR3 …
-
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
03 May 2024 20:20 GMT
The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this week. J&J JNJ announced a new plan to completely …